Differences in patient characteristics, disease-modifying treatment utilization, and relapse by race/ethnicity in Texas medicaid patients with multiple sclerosis

被引：0
|
作者：
Richards, K. M. [1 ]
Lawson, K. A. [1 ]
Nazareth, T. [2 ]
Yu, T. -C. [2 ]
Ko, J. J. [2 ]
Burton, E. [3 ]
Sasane, R. [2 ]
机构：
[1] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA
[2] Novartis Pharmaceut, Hlth Econ & Outcomes Res, E Hanover, NJ USA
[3] Novartis Pharmaceut, US Med Affairs, E Hanover, NJ USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P658
引用
收藏
页码：322 / 323
页数：2
相关论文
共 50 条
  • [1] Patterns of Disease-Modifying Treatment Use and Sociodemographic Characteristics in Multiple Sclerosis by Race and Ethnicity
    Perez, C. A.
    Elsehety, M. A.
    Agyei, P. B.
    Orlando, C. M.
    Singh, S. K.
    Lincoln, J. A.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (1_SUPPL) : 9 - 9
  • [2] Clinical and epidemiological characteristics of multiple sclerosis patients receiving disease-modifying treatment in Poland
    Kapica-Topczewska, Katarzyna
    Collin, Francois
    Tarasiuk, Joanna
    Chorazy, Monika
    Czarnowska, Agata
    Kwasniewski, Miroslaw
    Brola, Waldemar
    Bartosik-Psujek, Halina
    Adamczyk-Sowa, Monika
    Kochanowicz, Jan
    Kulakowska, Alina
    NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2020, 54 (02) : 161 - 168
  • [3] Disease-Modifying Treatment in Progressive Multiple Sclerosis
    Ciotti, John Robert
    Cross, Anne Haney
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2018, 20 (05)
  • [4] Current Disease-Modifying Treatment of Multiple Sclerosis
    Derwenskus, Joy
    MOUNT SINAI JOURNAL OF MEDICINE, 2011, 78 (02): : 161 - 175
  • [5] Disease-Modifying Treatment in Progressive Multiple Sclerosis
    John Robert Ciotti
    Anne Haney Cross
    Current Treatment Options in Neurology, 2018, 20
  • [6] Impact of Race on Use of Disease-Modifying Therapy in Multiple Sclerosis
    Hyland, Megan
    Cohen, Jeffrey
    Stone, Lael
    NEUROLOGY, 2013, 80
  • [7] The impact of sociodemographic characteristics on diagnosis and access to disease-modifying treatment for patients with multiple sclerosis in Morocco
    Lotfi, Rachid
    Chigr, Fatiha
    Najimi, Mohamed
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 67
  • [8] Audit of patients switching disease-modifying therapies for the treatment of multiple sclerosis
    Embrey, NH
    Woolmore, JA
    Hawkins, CP
    MULTIPLE SCLEROSIS, 2005, 11 : S159 - S159
  • [9] Prevalence of disease-modifying drug treatment gaps in patients with multiple sclerosis
    Joyeux, A.
    Kozma, C.
    Meletiche, D.
    Dickson, M.
    Bennett, R.
    JOURNAL OF NEUROLOGY, 2009, 256 : S163 - S163
  • [10] Association of Timing of Disease-Modifying Drug Treatment Initiation on Multiple Sclerosis Relapse Rates in Newly Diagnosed Patients
    Phillips, Amy
    Fang, Juanzhi
    Corvino, Frank
    Oliveri, David
    NEUROLOGY, 2016, 86
12345